Cargando…
Advances in prostate cancer imaging
Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound an...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113878/ https://www.ncbi.nlm.nih.gov/pubmed/30467517 http://dx.doi.org/10.12688/f1000research.14498.1 |
_version_ | 1783351093593374720 |
---|---|
author | Tangel, Matthew R. Rastinehad, Ardeshir R. |
author_facet | Tangel, Matthew R. Rastinehad, Ardeshir R. |
author_sort | Tangel, Matthew R. |
collection | PubMed |
description | Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future. |
format | Online Article Text |
id | pubmed-6113878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-61138782018-11-21 Advances in prostate cancer imaging Tangel, Matthew R. Rastinehad, Ardeshir R. F1000Res Review Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future. F1000 Research Limited 2018-08-24 /pmc/articles/PMC6113878/ /pubmed/30467517 http://dx.doi.org/10.12688/f1000research.14498.1 Text en Copyright: © 2018 Tangel MR and Rastinehad AR http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Tangel, Matthew R. Rastinehad, Ardeshir R. Advances in prostate cancer imaging |
title | Advances in prostate cancer imaging |
title_full | Advances in prostate cancer imaging |
title_fullStr | Advances in prostate cancer imaging |
title_full_unstemmed | Advances in prostate cancer imaging |
title_short | Advances in prostate cancer imaging |
title_sort | advances in prostate cancer imaging |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113878/ https://www.ncbi.nlm.nih.gov/pubmed/30467517 http://dx.doi.org/10.12688/f1000research.14498.1 |
work_keys_str_mv | AT tangelmatthewr advancesinprostatecancerimaging AT rastinehadardeshirr advancesinprostatecancerimaging |